Zeitpläne der EMA und der FDA für CAR-T-Therapien in der seltenen Onkologie August 27, 2025 Pharma & Biotech EMA vs FDA timelines for CAR-T in rare oncology differ, with FDA often granting faster approvals while EMA requires more data, affecting patient access. Weiter lesen
